Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients

Trial Profile

A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs ARO-ANG3 (Primary)
  • Indications Dyslipidaemias
  • Focus Adverse reactions
  • Sponsors Arrowhead Pharmaceuticals
  • Most Recent Events

    • 07 Jan 2019 According an Arrowhead Pharmaceuticals media release, first patient has been dosed in this study.
    • 13 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 16 Nov 2018 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top